Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synergistic effect of the inhibitors of RAF/MEK and AXL on KRAS-mutated ovarian cancer cells with high AXL expression.

Cancer science - 1 Jun 2020

Umemura Shiori, Sowa Yoshihiro, Iizumi Yosuke, Kitawaki Jo, Sakai Toshiyuki

Abstract excerpt

KRAS mutation is frequently seen in a subtype of ovarian cancer categorized as type 1. The KRAS-MAPK pathway, which is closely involved in type 1 cancer progression, is under the regulation of receptor tyrosine kinases (RTKs). AXL, one of the RTKs, has been reported to be overexpressed in ovarian cancer and contributes to the poor prognosis. However, there is no useful target-based agent against such gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Axl Receptor Tyrosine Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Ovarian Epithelial

Share to Coumarins

Share to Drug Synergism

Share to Proto-Oncogene Proteins p21(ras)

Share to Receptor Protein-Tyrosine Kinases

Share to Triazoles

Source

Open in PubMed Open full text

Identifiers

PMID: 32291856
DOI: 10.1111/cas.14414
PMCID: PMC7293078

Genes

AXL
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synergistic effect of the inhibitors of RAF/MEK and AXL on KRAS-mutated ovarian cancer cells with high AXL expression.PMID 32291856Read ↗

Molecular pathways: the basis for rational combination using MEK inhibitors in KRAS-mutant cancers.Semantic proximity Read ↗

The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.Semantic proximity Read ↗

Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.Semantic proximity Read ↗

Low‑dose trametinib and Bcl‑xL antagonist have a specific antitumor effect in KRAS‑mutated colorectal cancer cells.Semantic proximity Read ↗

Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.Semantic proximity Read ↗

Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation.Semantic proximity Read ↗

Synergistic therapeutic effects of metformin at a clinically relevant dosage in combination with chemotherapy via the AKT/mTOR pathway on ovarian cancerSemantic proximity Read ↗

Synergistic activity of sorafenib and betulinic acid against clonogenic activity of non-small cell lung cancer cells.Semantic proximity Read ↗

Horizontal Combination of MEK and PI3K/mTOR Inhibition in BRAF Mutant Tumor Cells with or without Concomitant PI3K Pathway Mutations.Semantic proximity Read ↗

Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cellsSemantic proximity Read ↗

[Growth inhibition of combined pathway inhibitors on KRAS mutated non-small cell lung cancer cell line].Semantic proximity Read ↗

Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.